# A Study of JMT101 in Patients With Metastatic Colorectal Cancer

> **NCT06089330** · PHASE2 · UNKNOWN · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 102 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer (mCRC)

## Interventions

- **DRUG:** JMT101
- **DRUG:** SG001
- **DRUG:** Irinotecan
- **DRUG:** Regorafenib (Stivarga)

## Key facts

- **NCT ID:** NCT06089330
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01
- **Primary completion:** 2024-07
- **Final completion:** 2024-12
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2023-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06089330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06089330, "A Study of JMT101 in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06089330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*